ClinicalTrials.gg
CompletedNCT04925739NINADOMUpdated Feb 1, 2023

Evaluation of the Comfort of a Continuous Positive Airway Pressure Nasal Mask in the Treatment of OSA Syndrome

An observational study in Apnea, Obstructive, sponsored by AGIR à Dom. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-01.

Sponsored by AGIR à Dom · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
20
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 201 studies in Sleep Apnea, Obstructive with a site in France — 39 open to participants now, 48 under way, 4 of them phase 3. Sleep Apnea, Obstructive · France.

Enrollment
63rd of 67
20 · median 140
Started
2021
with 16 others
Observational
67 of 201
18 open now
Registered
140th of 201
by date
Lead sponsor
4 of 201
AGIR à Dom

Among the 201 studies in Sleep Apnea, Obstructive with a site in France, this one is the 63rd largest by enrollment of the 67 observational ones that give a count, is one of 17 that started in 2021, is one of 67 observational ones, and was the 140th registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

39 of the 201 studies in Sleep Apnea, Obstructive with a site in France are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 201 studies in Sleep Apnea, Obstructive with a site in France, or all of them as a file.
02

Study summary

Continuous positive airway pressure (CPAP) is the first-line treatment for obstructive sleep apnea syndrome (OSA). It consists of a pressure generator connected to a mask applied to the patient's face. CPAP treatment is restrictive, and nearly a quarter of patients abandon it over the long term. Various factors can influence adherence to CPAP therapy, including adverse events associated with the mask. However, it is clear that compliance with CPAP treatment, even if it has tended to improve over the last 30 years, is still sub-optimal.

The "Air Liquide Medical Systems" company has developed a mask that aims to improve comfort and ease of use for the patient. This leaky nasal mask has a "silent" intentional leak port, which significantly reduces the noise caused by the escape of air. The noise associated with intentional leakage is one of the discomforts reported by patients and their spouses. In addition, this mask is equipped with a new generation headgear with adjustment indicators to assist the patient in fitting the mask. Optimal headgear fit is a prerequisite for comfort during treatment, as it reduces unintentional leakage.

The main objective is to evaluate, through a questionnaire, the comfort and general appreciation of a nasal mask equipped with a silent leak system and a headgear with adjustment aids, of patients with OSA treated with CPAP.

Secondary objectives are :

  1. To evaluate the appearance of CPAP side effects related to the mask,
  2. To collect the patient's appreciation of the mask headgear,
  3. To evaluate the discomfort caused by the nasal obstruction reported by the patient,
  4. To evaluate the daytime sleepiness of the patient,
  5. To study the parameters of the CPAP treatment.
Read the detailed description

Continuous positive airway pressure (CPAP) is the first-line treatment for obstructive sleep apnea syndrome (OSA). It consists of a pressure generator connected to a mask applied to the patient's face. CPAP treatment is restrictive, and nearly a quarter of patients abandon it over the long term. Various factors can influence adherence to CPAP therapy, including adverse events associated with the mask. Unintentional leaks, i.e. a leak between the pressure generator and the patient's upper airway, are among the most frequent. Therefore, optimizing the choice of mask is one of the main means used by medical-technical providers, in charge of installing CPAP and its technical follow-up at home. In order to cover the needs and anatomical particularities of the OSA patient population treated with CPAP, a large number of mask types and sizes are currently available on the market. However, it is clear that compliance with CPAP treatment, even if it has tended to improve over the last 30 years, is still sub-optimal.

The "Air Liquide Medical Systems" company has developed a mask that aims to improve comfort and ease of use for the patient. This leaky nasal mask has a "silent" intentional leak port, which significantly reduces the noise caused by the escape of air. The noise associated with intentional leakage is one of the discomforts reported by patients and their spouses. In addition, this mask is equipped with a new generation headgear with adjustment indicators to assist the patient in fitting the mask. Optimal headgear fit is a prerequisite for comfort during treatment, as it reduces unintentional leakage.

The main objective is to evaluate, through a questionnaire, the comfort and general appreciation of a nasal mask equipped with a silent leak system and a headgear with adjustment aids, of patients with OSA treated with CPAP.

After 30 days of use, secondary objectives are :

  1. To evaluate the appearance of CPAP side effects related to the mask (air leaks, injury to the nasal bridge, etc.)
  2. To collect the patient's appreciation of the mask headgear, which includes indications to help with the installation in the form of graduated markers, as well as the appreciation of the general aesthetics of the mask.
  3. To evaluate the discomfort caused by the nasal obstruction reported by the patient, in relation to the inclusion.
  4. To evaluate the daytime sleepiness of the patient, compared to the inclusion.
  5. To study the parameters of the CPAP treatment.
03

Conditions studied

  • Apnea, Obstructive

Keywords

  • Obstructive Sleep Apnea
  • Continuous Positive Airway Pressure
  • Mask
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

OSA patient, not previously treated with CPAP, who will be treated with a ResMed Airsense 10 CPAP and an Air Liquide Medical Systems NINA mask Patient whose CPAP treatment will be installed and monitored by the home care provider AGIRADOM.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patient over 18 years of age
  • Patient with OSA
  • Patient not previously treated with CPAP
  • A patient who will be treated with a "ResMed Airsense 10" CPAP and an "Air Liquide Medical Systems" NINA mask
  • Patient whose CPAP treatment will be installed and monitored by the home care provider AGIRADOM
  • Patient willing to participate in the research after adequate information and delivery of the information note
  • Patient affiliated to the social security system or beneficiary of such a system

Exclusion criteria

Exclusion Criteria:

  • NOSE questionnaire score greater than or equal to 10/20 at the time of CPAP installation
  • Patient with significant craniofacial deformities that do not allow the mask to be fitted correctly
  • Person deprived of liberty by judicial or administrative decision, person under legal protection (patient under guardianship or curators) Article L1121-8
  • Subject who receives more than 4500 euros in compensation for his or her participation in other research involving the human person in the 12 months preceding this study
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
20 participants (actual)
Patient registry
No

Groups and cohorts

  • OSA patients treated with CPAP

    OSA patient, not previously treated with CPAP, are treated with a "ResMed Airsense 10" CPAP and an "Air Liquide Medical Systems" NINA mask during 30 days, monitored by the home care provider AGIRADOM. After 30 days of CPAP treatment, 4 self-questionnaires are completed by the patient and parameters of the CPAP treatment (compliance, estimated unintentional leakage and therapeutic pressures) are collected.

    Other: Self-questionnaire on the comfort and general appreciation of a nasal mask · Other: Self-questionnaire on the appearance of CPAP side effects related to the mask · Other: Self-questionnaire on the patient's appreciation of the mask headgear, · Other: Self-questionnaire NOSE on the discomfort caused by the nasal obstruction · Other: Self-questionnaire Epworth on the daytime sleepiness · Other: To study the CPAP compliance · Other: To study the unintentional leakage · Other: To study the therapeutic pressures of CPAP

Interventions

  • OtherSelf-questionnaire on the comfort and general appreciation of a nasal mask

    Self-questionnaire on the comfort and general appreciation of a nasal mask after 30 days of use

  • OtherSelf-questionnaire on the appearance of CPAP side effects related to the mask

    Self-questionnaire on the appearance of CPAP side effects related to the mask (air leaks, injury to the nasal bridge, etc.) after 30 days of use

  • OtherSelf-questionnaire on the patient's appreciation of the mask headgear,

    Self-questionnaire NOSE (Nasal Obstruction Symptom Evaluation) on the patient's appreciation of the mask headgear, which includes indications to help with the installation in the form of graduated markers, as well as the appreciation of the general aesthetics of the mask, after 30 days of use.

  • OtherSelf-questionnaire NOSE on the discomfort caused by the nasal obstruction

    Self-questionnaire NOSE on the discomfort caused by the nasal obstruction reported by the patient, after 30 days of use, compared to the inclusion.

  • OtherSelf-questionnaire Epworth on the daytime sleepiness

    Self-questionnaire Epworth on the daytime sleepiness of the patient, after 30 days of treatment, compared to the inclusion. To study the parameters of the CPAP treatment.

  • OtherTo study the CPAP compliance

    To collect the treatment compliance through telemonitoring of the data recorded by the CPAP machine, during the 30 days of treatment.

  • OtherTo study the unintentional leakage

    To collect the unintentional leakage estimated by the CPAP machine, during the 30 days of treatment.

  • OtherTo study the therapeutic pressures of CPAP

    To collect the therapeutic pressures of CPAP, during the 30 days of treatment.

06

What researchers measure

Primary outcomes

  1. To evaluate the comfort and general appreciation of a nasal mask

    to evaluate, through a questionnaire, the comfort and general appreciation of a nasal mask equipped with a silent leak system and a headgear with adjustment aids, of patients with OSA treated with CPAP.

    Time frame: After 30 days of CPAP treatment

Secondary outcomes

  1. To evaluate the appearance of CPAP side effects related to the mask

    To evaluate the appearance of CPAP side effects, through a questionnaire, related to the mask (air leaks, injury to the nasal bridge, etc.)

    Time frame: After 30 days of CPAP treatment

  2. To collect the patient's appreciation of the mask headgear

    To collect, through a questionnaire, the patient's appreciation of the mask headgear, which includes indications to help with the installation in the form of graduated markers, as well as the appreciation of the general aesthetics of the mask.

    Time frame: After 30 days of CPAP treatment

  3. To evaluate the discomfort caused by the nasal obstruction reported by the patient

    To evaluate, trough the NOSE questionnaire, the discomfort caused by the nasal obstruction reported by the patient, compared to the inclusion.

    Time frame: After 30 days of CPAP treatment

  4. To evaluate the daytime sleepiness of the patient

    To evaluate the daytime sleepiness of the patient, through the Epworth questionnaire, compared to the inclusion.

    Time frame: After 30 days of CPAP treatment

  5. To collect the CPAP treatment compliance

    To collect the treatment compliance (average daily use) through telemonitoring of the data recorded by the CPAP machine.

    Time frame: During the 30 days of CPAP treatment

  6. To collect the unintentional leakage

    To collect the unintentional leakage estimated by the CPAP machine.

    Time frame: During the 30 days of CPAP treatment

  7. To collect the CPAP therapeutic pressures

    To collect the CPAP therapeutic pressures used.

    Time frame: During the 30 days of CPAP treatment

07

Study locations

1 site
  • Pauline Socquet
    Meylan, 38240, France
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Jan 2022, 3 months.

Of 258 non-industry observational studies under Sleep Apnea, Obstructive, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 63. This study's 3 months is below that.

Counting every sponsor, half of 294 studies reached it within 29 months; a quarter within 14 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2021
First posted
Jun 14, 2021
StartActual
Sep 22, 2021
Primary completionActual
Jan 21, 2022
CompletionActual
Jan 21, 2022
Last update
Feb 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04925739
Lead sponsor
AGIR à Dom
Collaborators
Air Liquide SA
Responsible party
Sponsor
First posted
Jun 14, 2021
Start date
Sep 22, 2021
Primary completion
Jan 21, 2022
Completion
Jan 21, 2022
Last update
Feb 1, 2023

Study contacts

LEBRET Marius
study director · AIR LIQUIDE MEDICAL SYSTEMS

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion